Firms ally to develop deuterium-based drugs for cancer, inflammation

Concert Pharmaceuticals granted Celgene the right to use its deuterated chemical entity technology to develop new deuterium-modified small compounds for cancer and inflammation. Concert will get an upfront payment and more than $300 million in possible milestone fees for each program selected for development, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI